To elucidate the molecular mechanism of sunitinib-mediated suppression of HCC, a panel of well-characterized signaling molecules was utilized in sunitinib-treated HCC cells. As shown in Fig. 5A, sunitinib had no effect on total STAT3 LDK378 supplier and pSTAT3(S727) in Sk Hep1 cells; however, this treatment dramatically inhibited pSTAT3(T705). A similar dose-dependent, but incomplete reduction in pSTAT3(T705) was observed in Hep G2 cells (Fig. 5A). In contrast, no inhibitory effects were observed on STAT5, pERK-1/2, and p38 MAPK in either cell line. Only modest inhibitory effects were detected on pSTAT5 and pAkt with more notable

effects in Sk Hep1 cells (Fig. 5A). To further confirm whether STAT3 is involved in the sunitinib-mediated suppression of HCC, we utilized wtSTAT3 and a dominant negative variant of STAT3. This dnSTAT3 inhibited the proliferation of Sk Hep1 and Hep G2 (Fig. 5B), induced the apoptosis (Fig. 5C), and dramatically decreased colony formation (Fig. 5D). In contrast, overexpression of wtSTAT3 rescued the sunitinib-mediated suppression of proliferation (Fig. 5E) and apoptosis Enzalutamide price (Fig. 5F). These results indicate that STAT3 is involved in sunitinib-mediated

inhibition of HCC cell growth. To investigate the effect of sunitinib on blocking tumor growth in vivo, tumor-bearing mice were orally administered sunitinib. Monthly MRI was used to monitor change in tumor size. The results in Fig. 6A demonstrate progressive tumor growth from 130 mm3 to 180 mm3 in vehicle-treated tumor-bearing mice, whereas sunitinib-treated mice demonstrate a continual decrease in tumor burden from 130 mm3 to 100 mm3 3 months posttreatment. Western blot revealed decreased levels of pSTAT3 (T705) in the tumors from sunitinib-treated mice compared to vehicle-treated mice. Survivin, a direct downstream target of STAT3, is also reduced in the sunitinib-treated tumors (Fig. 6B). However, no detectable differences were found in the levels of ERK, pERK, Akt, pAkt, and total STAT3. In a second in

vivo analysis, dnSTAT3-transfected Tag tumorigenic hepatocytes do not produce tumors in C57BL/6 mice, whereas the empty vector-transfected hepatocytes demonstrate progressive tumor growth (Fig. 6C). These results indicate that sunitinib treatment induces the partial regression of established this website orthotopic HCC and is associated with a reduction in pSTAT3 within the tumor. Suppression of STAT3 is crucial in both innate and adaptive immune responses against tumors.8, 21 Therefore, we considered that sunitinib treatment may activate the tumor-specific immune response. Sunitinib treatment of tumor-bearing mice dramatically enhanced the accumulation of adoptively transferred TCR-I T cells following immunization (Fig. 7A,B). This level of accumulation was consistently higher than that observed in normal C57BL/6 mice (17% versus 6.9%).